Skip navigation.

HOME > Publications > Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences

Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences

J-STAGE

Project Euclid

CiNii

PubMed Logo

The Proceedings of the Japan Academy, Series B was founded in 1912 as the Proceedings of the Imperial Academy by the then Imperial Academy of Japan (now the Japan Academy). The Journal was split to the Proceedings of the Japan Academy, Series A and Series B in 1977. PJA Series B publishes reviews and original articles in broad fields of natural sciences, such as chemistry, physics, astronomy, earth sciences, biology, engineering, agricultural sciences and medical sciences. All manuscripts are evaluated at least by two reviewers. Ten issues are published per year. The entire content is now freely available online through J-STAGE.

Vol. 90 No. 9 (2014)


Reviews
Use of gnotobiotic mice to identify and characterize key microbes responsible for the development of the intestinal immune system
Yoshinori UMESAKI
Proc. Jpn. Acad., Ser. B, Vol. 90, 313-332 (2014) [abstract] [PDF]
Reminiscence of phospholipase B in Penicillium notatum
Kunihiko SAITO
Proc. Jpn. Acad., Ser. B, Vol. 90, 333-346 (2014) [abstract] [PDF]
Original Articles
Cause and risk of catastrophic eruptions in the Japanese Archipelago
Yoshiyuki TATSUMI and Keiko SUZUKI-KAMATA
Proc. Jpn. Acad., Ser. B, Vol. 90, 347-352 (2014) [abstract] [PDF]
Novel plasma biomarker surrogating cerebral amyloid deposition
Naoki KANEKO, Akinori NAKAMURA, Yukihiko WASHIMI, Takashi KATO, Takashi SAKURAI, Yutaka ARAHATA, Masahiko BUNDO, Akinori TAKEDA, Shumpei NIIDA, Kengo ITO, Kenji TOBA, Koichi TANAKA and Katsuhiko YANAGISAWA
Proc. Jpn. Acad., Ser. B, Vol. 90, 353-364 (2014) [abstract] [PDF]
Ionizing radiation-induced XRCC4 phosphorylation is mediated through ATM in addition to DNA-PK
Shoji IMAMICHI, Mukesh Kumar SHARMA, Radhika Pankaj KAMDAR, Mikoto FUKUCHI and Yoshihisa MATSUMOTO
Proc. Jpn. Acad., Ser. B, Vol. 90, 365-372 (2014) [abstract] [PDF]
Cover Illustration
Plasma biomarker for detection of preclinical Alzheimer’s disease

 Alzheimer’s disease (AD) is the most common dementia and the number of patients is growing worldwide. Biomarkers to identify people at risk of AD before the onset of cognitive decline are urgently required, because disease-modifying drugs are likely to be effective only in the preclinical stage. Given that an early and invariable neuropathological feature of AD is the deposition of amyloid β-protein (Aβ) as fibrils (amyloid) in the brain, investigators are seeking biomarkers as surrogates of cerebral amyloid deposition. So far, two diagnostic procedures, i.e., cerebrospinal fluid examination and amyloid imaging by positron emission tomography (PET), have been developed for this purpose. However, the former is invasive and the latter is costly and not widely available. Thus, plasma Aβs have been extensively studied as potential alternatives. Unfortunately, the results so far have not been satisfactorily informative on the state of amyloid deposition in cross-sectional studies. As reported in this issue (pp. 353-364), Dr. Kaneko et al. measured Aβs and Aβ-related peptides in plasma samples obtained from aged individuals who all underwent amyloid imaging by PET, employing highly sensitive immunoprecipitation-mass spectrometry. In this study, they successfully identified, for the first time, a plasma biomarker that serves as a precise surrogate of cerebral amyloid deposition. The cover picture shows the result of regression analysis between PiB-PET images and plasma APP669-711/Aβ1-42 levels in the subjects examined; brain areas that showed statistically significant correlations are visualized in yellow-red gradation on the 3D-rendered standard brain (viewing from the medial side (upper) and lateral side (lower) of both hemispheres). These images clearly demonstrate that plasma APP669-711/Aβ1-42 is an excellent surrogate of cerebral amyloid deposition. As the authors noted, their novel biomarker is expected to be a powerful community screening tool for detection of preclinical AD, and thus it should facilitate disease-modifying clinical trials.

Yo-ichi Nabeshima
Director
Institute of Biomedical Research and Innovation
Foundation for Biomedical Research and Innovation

↑Go to TOP